MT 2766
Alternative Names: Adjuvanted COVID-19 vaccine - Glaxosmithkline/Medicago; Coronavirus-like particle COVID-19 vaccine; COVID-2019 vaccine - Glaxosmithkline/ Medicago; COVIFENZ; CoVLP adjuvanted vaccine with AS03 adjuvant; GSK-4362620A; MT-2766; Plant-derived COVID-19 vaccine - Glaxosmithkline/Medicago; Recombinant coronavirus-like particle vaccineLatest Information Update: 15 Jun 2023
At a glance
- Originator GlaxoSmithKline; Medicago
- Developer Medicago; Mitsubishi Tanabe Pharma Corporation
- Class COVID-19 vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 02 Jun 2023 Medicago withdraws a phase III trial in COVID-2019 infections (Prevention, In adults) in Canada (IM) prior to enrolment (NCT05040789)
- 07 Feb 2023 Medicago terminates a phase-I/II trial due to ethical reason so as to prioritise the ancestral vaccination in COVID-2019 infections (Prevention) in Japan (IM) (NCT05065619) (jRCT2051210093)
- 05 May 2022 Adverse event data from a phase II/III trial in COVID-2019 infections released by Medicago